C&R Research Inc.

359090· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩2,200+0.92%

2026-09-18

Financials

Valuation Metrics

C&R Research Inc.'s Market Cap is ₩253B. At end of 2025 it was ₩517B. Ranked #2205 of 2,421 in KR market (top 91%), #1444 of 1,640 on KOSDAQ (top 88%), #219 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 95%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	25.29B KRW	KR#2,205/2,421 Sec#219/231
Revenue	63.55B KRW	KR#1,664/2,421 Sec#110/231
Net Income	-1.04B KRW	KR—/2,421 Sec—/231
Total Assets	93.59B KRW	KR#1,834/2,421 Sec#146/231
Net Assets	46.37B KRW	KR#1,958/2,421 Sec#166/231
Employees	518	KR#482/2,421 Sec#40/231
Value
P/B	0.55x	KR#879/2,421 Sec#44/231
P/S	0.40x	KR#764/2,421 Sec#26/231
Profitability
ROE	-2.25%	KR#1,702/2,421 Sec#119/231
ROA	-1.11%	KR#1,689/2,421 Sec#118/231
Op. Margin	-0.72%	KR#1,671/2,421 Sec#113/231
Revenue Growth	-1.69%	KR#1,614/2,421 Sec#158/231
Financial Health
Debt Ratio	101.86%	KR#1,573/2,421 Sec#181/231
Total Debt	15.15B KRW	KR#1,493/2,421 Sec#126/231
Cash	13.48B KRW	KR#1,505/2,421 Sec#122/231
Current Ratio	1.06x	KR#1,664/2,421 Sec#166/231
Dividend
Div. Yield	2.27%	KR#816/2,421 Sec#42/231
Div. Growth	0.00%	KR—/2,421 Sec—/231
Performance
1Y Return	-56.44%	KR#2,158/2,421 Sec#202/231
1M Return	10.61%	KR#468/2,421 Sec#31/231
From 52W High	-62.65%	KR#1,954/2,421 Sec#158/231
1Y MDD	-69.17%	KR#1,957/2,421 Sec#167/231
Trading
Volume	6,571 shares	KR#2,054/2,421 Sec#196/231
Trading Value	14.4M KRW	KR#2,216/2,421 Sec#214/231
Foreign Own.	0.48%	KR#2,212/2,421 Sec#212/231
Per Share
EPS	-91 KRW	KR—/2,421 Sec—/231
BPS	4,034 KRW	KR#1,660/2,421 Sec#120/231

Company Info

CEO 윤문태

Employees 518

Founded 2020

HQ 서울특별시 강남구, KR

동사는 2000년 법인 전환 설립되었으며, 2021년 엔에이치기업인수목적17호와 합병 후 코스닥시장 상장함. 임상시험수탁기관으로 신약개발 임상시험 설계, 컨설팅, 모니터링, 데이터 관리 등 전 영역 서비스를 제공하고 있음. 임상시험 IT 솔루션 LeadTrial EDC, CTMS, CsafeR 개발 완료하며, 글로벌 시장 진출 위해 서울대병원과 협력하여 다지역 임상시험 서비스 제공하고 있음. 씨엔알리서치는 2020년에 설립되었으며 서울특별시 강남구에 본사를 두고 있습니다.